PANACEABIO
Panacea Biotec Limited (PANACEABIO) Stock Analysis
Panacea Biotec Limited develops vaccines, biosimilars, and pharmaceutical formulations for India and export markets. It has manufacturing facilities for sterile and oral dosage forms. The company is known for vaccine partnerships and public health supply. It is listed on Indian stock exchanges as a biopharma player.
Healthcare › Biotechnology
₹359.70
+4.19% 1W | -20.00% 52W
Market Cap
2.2k CR
P/E Ratio
–
52W High
₹647
52W Low
₹292.4
Div. Yield
0%
Beta
0.3
50 DMA
₹383.7
200 DMA
₹401.6
Profit Margin
-1.1%
Inst. Own.
0.2%
📉 CONSOLIDATING DOWN
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 | 141.13 | 165.19 | 166.75 | 199.57 |
| Expenses | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 | 158.92 | 153.45 | 164.18 | 193.90 |
| Operating Profit | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 | -17.79 | 11.74 | 2.57 | 5.67 |
| OPM % | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% | -12.61% | 7.11% | 1.54% | 2.84% |
| Other Income | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 | 9.10 | 5.05 | 5.26 | 6.98 |
| Interest | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 | 2.14 | 1.85 | 1.20 | 1.18 |
| Depreciation | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 | 8.34 | 8.45 | 7.88 | 7.90 |
| Profit before tax | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 | 3.57 |
| Tax % | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% | -26.92% | 40.06% | -20.00% | 38.38% |
| Net Profit | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1.00 | 2.20 |
| EPS in Rs | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 640 | 673 |
| Expenses | 643 | 541 | 505 | 509 | 591 | 484 | 548 | 674 | 558 | 579 | 584 | 644 | 670 |
| Operating Profit | 44 | 112 | 39 | 84 | -134 | 60 | 77 | -13 | -98 | -20 | -25 | -5 | 2 |
| OPM % | 6% | 17% | 7% | 14% | -29% | 11% | 12% | -2.0% | -21% | -3.5% | -4.4% | -0.7% | 0.3% |
| Other Income | 28 | 70 | 62 | 8 | 338 | -21 | 9 | 1,687 | 154 | 62 | 55 | 36 | 26 |
| Interest | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 6 | 6 |
| Depreciation | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 33 | 33 |
| Profit before tax | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 | -7 | -10 |
| Tax % | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% | -3% | |
| Net Profit | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | -7 | -9 |
| EPS in Rs | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | -0.88 | -1.16 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 12.0% | 0.0% | 0.0% |
| Profit CAGR | 21.0% | 13.0% | 5.0% |
Shareholding Pattern
Promoters72.48%
FIIs1.06%
DIIs1.80%
Public24.65%
Promoters72.48%
FIIs1.36%
DIIs1.85%
Public24.31%
Promoters72.48%
FIIs1.60%
DIIs1.96%
Public23.96%
Promoters72.48%
FIIs2.31%
DIIs2.25%
Public22.96%
Promoters72.48%
FIIs2.75%
DIIs2.47%
Public22.31%
Promoters73.59%
FIIs0.18%
DIIs0.43%
Public25.80%
Promoters73.59%
FIIs0.27%
DIIs0.84%
Public25.30%
Promoters72.48%
FIIs1.16%
DIIs1.49%
Public24.86%
Promoters72.48%
FIIs1.60%
DIIs1.96%
Public23.96%
Promoters72.48%
FIIs2.75%
DIIs2.47%
Public22.31%
PANACEABIO
Holdings Analysis
Key strengths & risk signals
48
Overall
50
Fundamental
47
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 20.0% in the last year.
WEAK POSITION! Current price (359.7) is below both moving averages.
WEAK! Trading at 19.0% of 52W range - near yearly lows.
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 80,917 vs down days: 77,854. Ratio: 1.04x
NEUTRAL! RSI at 44.5 - balanced momentum.
Fundamental & Technical Analysis
48Overall
50Fundamental
47Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 10.1% (GOOD, 11/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -1.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 25.66% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (383.7) is below 200-day average (401.6) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (359.7) is below both moving averages.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
1/10
POOR YEAR! Stock declined 20.0% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 80,917 vs down days: 77,854. Ratio: 1.04x
RSI
3/5
NEUTRAL! RSI at 44.5 - balanced momentum.
52W Range
1/5
WEAK! Trading at 19.0% of 52W range - near yearly lows.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - 4.2% (1 week), -2.0% (1 month), -34.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PANACEABIO | ₹359.70 | – | -1.1% | 10.1% | – | -20.0% | 48 | CONSOLIDATING DOWN | -42.5% | +360.0% | +19.7% | +19.7% |
| DCAL | ₹149.80 | 146.9 | 0.6% | 9.0% | 21.0% | -45.7% | 50 | CONSOLIDATING DOWN | -347.9% | -367.3% | -4.2% | -20.4% |
| 3BBLACKBIO | ₹1,446.40 | 22.1 | 36.3% | 31.9% | 32.2% | +26.8% | 73 | APPROACHING RESISTANCE | -24.6% | -1.0% | +50.9% | -5.4% |
| HALEOSLABS | ₹1,532.40 | 29.3 | 4.9% | 0.3% | 14.7% | +37.4% | 64 | APPROACHING RESISTANCE | -38.1% | +550.0% | -11.6% | -2.9% |
| LYKALABS | ₹87.80 | – | -6.6% | 13.3% | – | -15.6% | 57 | BREAKDOWN | +133.3% | -127.6% | +28.2% | +51.1% |
| ZOTA | ₹1,409.30 | – | -17.0% | 56.7% | – | -11.1% | 56 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| SUPRIYA | ₹886.00 | 35.9 | 22.7% | 21.2% | 32.5% | +18.4% | 86 | CONSOLIDATING UP | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹520.60 | 38.4 | 26.5% | 9.4% | 15.7% | -22.2% | 70 | BREAKDOWN | -14.1% | +21.8% | -17.4% | +24.9% |
Data from TradeAlone · Updated daily
